Date created: | Last Updated:

Category: Data

Description: Cardiovascular diseases (CVD), defined as a set of dysfunctions in the heart and blood vessels, are the leading cause of death worldwide, accounting for one in five deaths in Europe (ESC, 2022). Although CVDs cover a wide range of diseases, ischemic heart disease, namely acute myocardial infarction (AMI), stands out both in Portugal and in Europe (EUROSTAT, 2022).Portugal has an ageing population, and CVD is prominent in the country's epidemiological profile. The analysis of mortality indicators shows that, although deaths associated with AMI continue to decline in Portugal, this disease continues to show higher mortality rates in age groups below 65 years (INE, 2021). If, on the one hand, these data reveal the effectiveness of implementing disease prevention strategies and improving diagnosis, on the other hand, they alert to the fact that Portugal stays behind some European Union (EU) countries in terms of mortality due to preventable and treatable causes (OCDE, 2021; OPSS, 2022).Treating people with AMI or at high risk of developing it carries a high financial cost and places a considerable strain on health systems (Smith et al., 2012; Townsend et al., 2022; Visseren et al., 2021). On the other hand, the negative disease impact on a person's quality of life and average life expectancy is highlighted as an important health outcome (Boehme et al., 2022). Hence, this fact suggests the investment needs to reduce or prevent risk factors in the community (OCDE, 2021; OPSS, 2022).Adherence to pharmacological treatment plays a key role in satisfactory health outcomes, such as reduced symptoms, improved quality of life, and reduced readmissions, morbidity, and mortality (Arnett et al., 2019; Padilha et al., 2021). In developed countries, studies indicate that about 50% of people with chronic diseases choose not to start their medication, stop treatment prematurely, or not follow the daily routine of taking their medication as prescribed (Kronish et al., 2021), resulting in worse clinical outcomes (Fanaroff et al., 2020; Foley et al., 2021). Moreover, studies highlight that people with low literacy and low process involvement in managing their disease have a greater likelihood of easily abandoning their treatment (Beauchamp et al., 2022; Foley et al., 2021; Simon et al., 2021). In a recently published scoping review, it is clear that few interventions for people with an AMI aim to increase levels of health literacy and promote behavioural changes adjusted to the assumptions underlying a healthier lifestyle (Beauchamp et al., 2022). These conditions, including the way health services are structured and the lack of support for health professionals in developing their emotional competencies to deal with this type of patient (Fino et al., 2020; A. P. Macedo et al., 2021; A. P. M. de C. Macedo et al., 2020),However, evidence has shown that in 18 countries, hypertension programmes could be implemented efficiently (reported as health gains for the system and patient) if the Primary Health Care (PHC) domain was involved and interoperable with hospital-based efforts (WHO, 2021).There is a significant gap between evidence-based AMI prevention on the one hand and the realisation of preventive measures and target-level achievements in the real world on the other (Boehme et al., 2022). At the moment that international health policies (WHO, 2021; OPSS, 2022) try to redefine professional priorities by appealing to the prioritisation of prevention programmes headed to the person at risk or post-myocardial infarction, it is pertinent to investigate the role of health professionals and health organisations in its planning, implementation, and assessment. Through summarising the state-of-the-art, we aim to (1) empirically explore and understand data capable of characterising therapeutic programmes by quality indicators (directed to the person and health systems), implementation settings (hospital, primary health care, or interoperable intervention), and communications between patients, health professionals, and systems (channel types); (2) obtain an overview of the methodological strategies most used by researchers to intervene in the phenomenon; and (3) indicate possible approaches that could be used to define an effective strategy for future therapeutic programme implementations concerning this topic. Thus, we hope to be able to answer the following research question: "What health indicators are associated with therapeutic programmes aimed at patients post-myocardial infarction or at risk of it?"